{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:00:49Z","timestamp":1790211649684,"version":"4.1.0"},"reference-count":7,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,6,23]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Since December 2019, coronavirus disease 2019 (COVID-19) has been an international public health emergency. The possibility of COVID-19 should be considered primarily in patients with new-onset fever or respiratory tract symptoms. However, these symptoms can occur with other viral respiratory illnesses. We reported a case of severe acute respiratory syndrome coronavirus 2 and influenza A virus coinfection. During the epidemic, the possibility of COVID-19 should be considered regardless of positive findings for other pathogens.<\/jats:p>","DOI":"10.1136\/bcr-2020-236812","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T02:24:52Z","timestamp":1593656692000},"page":"e236812","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Coinfection with SARS-CoV-2 and influenza A virus"],"prefix":"10.1136","volume":"13","author":[{"given":"Yuki","family":"Kondo","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6700-7675","authenticated-orcid":false,"given":"Shinichi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"2025082712323443000_13.7.e236812.1","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"2025082712323443000_13.7.e236812.2","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6266","article-title":"Rates of co-infection between SARS-CoV-2 and other respiratory pathogens","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"2025082712323443000_13.7.e236812.3","article-title":"The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China","volume":"382","author":"Ding","year":"2020","journal-title":"J Med Virol"},{"key":"2025082712323443000_13.7.e236812.4","unstructured":"National Institutes of health (NIH). coronavirus disease 2019 (COVID-19) treatment guidelines. NIH 2020."},{"key":"2025082712323443000_13.7.e236812.5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025082712323443000_13.7.e236812.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2020.04.007"},{"key":"2025082712323443000_13.7.e236812.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with Favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-236812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:32:45Z","timestamp":1756323165000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-236812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":7,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7,1]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/bcr-2020-236812"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-236812","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}